NCT05222529 - Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Glycopyrronium (Bromide) in Children (6 to Less Than 12 Years) With Asthma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 29, 2022

Primary Completion Date

July 30, 2027

Study Completion Date

August 30, 2027

Conditions

Asthma

Interventions

DRUG

Glycopyrronium bromide 25ug

25μg Glycopyrronium bromide capsules for oral inhalation via Breezhaler

DRUG

Placebo

Placebo to Glycopyrronium bromide capsules for oral inhalation via Breezhaler

DRUG

Glycopyrronium bromide 12.5ug

12.5ug Glycopyrronium bromide capsules for oral inhalation via Breezhaler

Trial Locations (23)

1033

RECRUITING

Novartis Investigative Site, Budapest

1309

RECRUITING

Novartis Investigative Site, Sofia

3300

RECRUITING

Novartis Investigative Site, Eger

4032

RECRUITING

Novartis Investigative Site, Debrecen

5400

RECRUITING

Novartis Investigative Site, Sevlievo

6529

RECRUITING

Novartis Investigative Site, George

7002

COMPLETED

Novartis Investigative Site, Rousse

7400

WITHDRAWN

Novartis Investigative Site, Kaposvár

7531

RECRUITING

Novartis Investigative Site, Cape Town

7900

RECRUITING

Novartis Investigative Site, Szigetvár

8800

WITHDRAWN

Novartis Investigative Site, Nagykanizsa

730006

RECRUITING

Novartis Investigative Site, Ibagué

01010

WITHDRAWN

Novartis Investigative Site, Guatemala City

01015

RECRUITING

Novartis Investigative Site, Guatemala City

H-1083

RECRUITING

Novartis Investigative Site, Budapest

33-100

RECRUITING

Novartis Investigative Site, Tarnów

90-329

RECRUITING

Novartis Investigative Site, Lodz

08950

RECRUITING

Novartis Investigative Site, Esplugues de Llobregat

08208

RECRUITING

Novartis Investigative Site, Sabadell

08035

RECRUITING

Novartis Investigative Site, Barcelona

06800

WITHDRAWN

Novartis Investigative Site, Mérida

SE5 9RS

RECRUITING

Novartis Investigative Site, London

ST4 6QG

RECRUITING

Novartis Investigative Site, Stoke-on-Trent